Navigation Links
Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
Date:10/27/2009

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia. NKTR-118, an oral peripherally-acting opioid antagonist, is an investigational product candidate in clinical development for the treatment of opioid-induced constipation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

In the phase II double blind, randomized, placebo-controlled study of 208 patients with opioid-induced constipation, NKTR-118 achieved the primary endpoint of change from baseline in spontaneous bowel movements (SBMs). Patients receiving either 25 mg or 50 mg of oral NKTR-118 once daily had a significantly greater change from baseline in SBMs during the first week of treatment than patients receiving placebo. The mean change from baseline in SBMs per week for patients receiving 25 mg NKTR-118 was 3.6 versus 1.9 in the placebo group (p= 0.002). Patients receiving 50 mg NKTR-118 had a mean change from baseline in SBMs per week of 4.4 versus 1.9 in the placebo group (p=0.0001). The increase from baseline in SBMs versus placebo averaged over the four-week treatment period was significant for both the 25 mg (p=0.002) and 50 mg (p<0.0001) dose groups. Results for the 5 mg dose of NKTR-118 were not significant.

The study also showed that there was a statistically significant difference in median time to first SBM for patients in the 25 mg and 50 mg dose cohorts as compared to placebo. Median time to first SBM for patients in the 25 mg dose cohort was 6.6 hours as compared to placebo which was 48.6 hours (p=0.001), and for patients in the 50 mg dose cohort, median time to first SBM was 2.9 hours as compared to placebo,
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
2. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
3. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
4. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
5. Delcath Systems, Inc. Completes Phase III Study Enrollment
6. AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
7. Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections
8. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
9. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
10. Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
11. TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... Oct. 1, 2014 Quantum Materials Corp ... production of photoactive quantum dots for use in ... offering numerous advantages for solar power generation, the ... of quantum dots with which to develop thin ... from commercial utilization and acceptance. The company is ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... Every Four-Week Subcutaneous Golimumab Also Experienced ... and Disease Activity, PARIS, June 11 Findings ... every four-week subcutaneous injections of,golimumab (CNTO 148) 50 mg ... in the signs and symptoms of,rheumatoid arthritis (RA) as ...
... maintenance ... compared to placebo, BRIDGEWATER, N.J., June 10 Sanofi-aventis,announced ... (zolpidem,tartrate extended-release) CIV tablets 12.5 mg provided significant,improvement in sleep ... patients with co-morbid insomnia and major depressive disorder,(MDD) who were ...
Cached Medicine Technology:Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 2Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 3Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 4Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 5Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 6Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 7Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 8Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 2Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 3Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 4Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 5
(Date:10/1/2014)... eye, the brain of a rat and a robot ... a QUT leading robotics researcher. , Dr Michael ... new study uses new computer algorithms to enable robots ... , "This is a very Frankenstein type of project," ... a thing together because we,re taking the eyes of ...
(Date:10/1/2014)... that encourages people to keep their "eyes on the ... exercise. When walking, staying focused on a specific target ... and help people walk there faster, psychology researchers have ... while looking around the environment naturally, offers a new ... are less interested in exercise if physical activity seems ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... Hills, California (PRWEB) October 01, 2014 ... expert, Dr. Kathleen Mojas is celebrating 20 years of ... has assisted hundreds of people to achieve greater joy ... an important list of warning signs and suggestions for ... , Dr. Mojas explains: “Believe it or not, ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... LANCASTER, Pa., June 12 Herley Industries,Inc. (Nasdaq: ... third quarter,ended May 4, 2008. Herley reported net sales ... or 13% from the third quarter of the prior,fiscal ... of $0.27 per share including,the impact of a litigation ...
... allow physicians to more accurately diagnose and treat ... University to Syntermed, an Atlanta-based nuclear medicine imaging ... phase analysis (MHPA), a technology developed by Emory ... PhD. , MHPA is designed to quickly and ...
... and molecular machinery is pointing toward new drugs and ... emerging era of personalized medicine, in which doctors aim ... for the right patient, also brings concerns about genetic ... , The American Association for the Advancement of ...
... TULSA, Okla., June 12 Do you know ... those individuals and,organizations working to improve Oklahoma,s health. ... of those who are making a,significant difference in ... the deadline of Friday, Aug. 1., Nominations ...
... Clear Need for Continued Industry Commitment to Health IT Privacy and ... ... June 12 As consumer options for online,health management expand, there ... complex technologies contribute to,better health and added convenience. Wide-spread adoption requires ...
... June 12 Best Practices, LLC,conducted this study ... used by companies across various industries to measure,the ... pharmaceutical industry, number of sales calls is most ... manufacturing,companies employ year over year account revenue growth ...
Cached Medicine News:Health News:Herley Reports Third Quarter Results 2Health News:Herley Reports Third Quarter Results 3Health News:Herley Reports Third Quarter Results 4Health News:Herley Reports Third Quarter Results 5Health News:Herley Reports Third Quarter Results 6Health News:Herley Reports Third Quarter Results 7Health News:Herley Reports Third Quarter Results 8Health News:Herley Reports Third Quarter Results 9Health News:Herley Reports Third Quarter Results 10Health News:Herley Reports Third Quarter Results 11Health News:Herley Reports Third Quarter Results 12Health News:Herley Reports Third Quarter Results 13Health News:Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients 2Health News:AAAS hosts June 20 conference on personalized medicine 2Health News:Nominations Accepted for 2008 'Champions of Health' Awards 2Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 2Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 3Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 4Health News:Benchmarking Study Report on Sales Performance Management 2
... Agilis Steerable Introducer helps physicians ... right or left atrium. With ... tip, and radiopaque tip marker, ... the agility and stability needed ...
... 70 RF Generator introduces maximum ... every day, in every ablation ... and the CARTO EP Navigation ... Catheter provide clinicians with a ...
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
Medicine Products: